Drug differences between ACE inhibitors in experimental settings and clinical practice.

In recent years, growing evidence has suggested a beneficial effect from the use of angiotensin converting enzyme (ACE) inhibitors after myocardial infarction. Since important differences between the structure and effects of the various ACE inhibitors exist, differences in outcome can be expected. This review discusses the structural, pharmacodynamic and pharmacokinetic differences between ACE inhibitors administered after myocardial infarction, both in experimental settings and in clinical practice.